Eurostars Funds IMPACT2 To Establish A Break-Through Translational AMR Platform

Eurostars Funds IMPACT2 To Establish A Break-Through Translational AMR Platform

BioSystemsTechnology, BioVersys and Voxcan join forces to establish IMPACT2 – an Innovative Multifaceted Platform for Antimicrobial Commercialisation Transformation Powered by Eurostars – a joint programme co-funded by EUREKA member countries and the European Union Horizon 2020 Framework Programme.

BioSystems Technology, BioVersys and Voxcan announce funding for a total of about € 840’000, by Eurostars over a 3-year period for IMPACT2, a break-through innovative translational AMR platform that will expedite the development of novel new medicines in the fight against antimicrobial resistance.

Full PR available here